[go: up one dir, main page]

BRPI0917993B8 - composições de célula-tronco mesenquimal purificada - Google Patents

composições de célula-tronco mesenquimal purificada

Info

Publication number
BRPI0917993B8
BRPI0917993B8 BRPI0917993A BRPI0917993A BRPI0917993B8 BR PI0917993 B8 BRPI0917993 B8 BR PI0917993B8 BR PI0917993 A BRPI0917993 A BR PI0917993A BR PI0917993 A BRPI0917993 A BR PI0917993A BR PI0917993 B8 BRPI0917993 B8 BR PI0917993B8
Authority
BR
Brazil
Prior art keywords
stem cell
mesenchymal stem
purified
cell compositions
purified mesenchymal
Prior art date
Application number
BRPI0917993A
Other languages
English (en)
Inventor
Danilkovich Alla
Ton Christopher
Young Randal
e newman Robert
Tom Samson
Wang Zhanling
Original Assignee
Mesoblast Int Sarl
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917993(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mesoblast Int Sarl, Osiris Therapeutics Inc filed Critical Mesoblast Int Sarl
Publication of BRPI0917993A2 publication Critical patent/BRPI0917993A2/pt
Publication of BRPI0917993B1 publication Critical patent/BRPI0917993B1/pt
Publication of BRPI0917993B8 publication Critical patent/BRPI0917993B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composições de célula-tronco mesenquimal purificada e métodos de purificação de composições de célula-tronco mesenquimal purificada. a presente invenção refere-se a uma ou mais composições farmacêuticas de célula-tronco purificada e métodos de produção que utilizam a filtração centrífuga. são descritos também limiares para a administração intravenosa das composições farmacêuticas de célula-tronco mesenquimal que compreendem produtos animais residuais.
BRPI0917993A 2008-08-14 2009-08-14 composições de célula-tronco mesenquimal purificada BRPI0917993B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8889808P 2008-08-14 2008-08-14
US61/088,898 2008-08-14
PCT/US2009/053891 WO2010019886A1 (en) 2008-08-14 2009-08-14 Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

Publications (3)

Publication Number Publication Date
BRPI0917993A2 BRPI0917993A2 (pt) 2017-10-10
BRPI0917993B1 BRPI0917993B1 (pt) 2020-12-29
BRPI0917993B8 true BRPI0917993B8 (pt) 2021-05-25

Family

ID=41669330

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917993A BRPI0917993B8 (pt) 2008-08-14 2009-08-14 composições de célula-tronco mesenquimal purificada

Country Status (14)

Country Link
US (5) US8637004B2 (pt)
EP (3) EP2318519B1 (pt)
JP (6) JP6025329B2 (pt)
AR (2) AR073069A1 (pt)
AU (1) AU2009281809B2 (pt)
BR (1) BRPI0917993B8 (pt)
CA (1) CA2733985C (pt)
DK (1) DK2318519T3 (pt)
ES (1) ES2608974T3 (pt)
IL (1) IL211214A0 (pt)
MX (2) MX362512B (pt)
NZ (2) NZ591146A (pt)
WO (1) WO2010019886A1 (pt)
ZA (1) ZA201101858B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005093044A1 (en) 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
MX362512B (es) 2008-08-14 2019-01-22 Mesoblast Int Sarl Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
MX339624B (es) 2008-08-20 2016-06-02 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
ITGE20120034A1 (it) * 2012-03-28 2013-09-29 Carlo Tremolada Preparato e metodo per la produzione di un preparato comprendente cellule staminali mesenchimali
JP2013252126A (ja) * 2012-05-08 2013-12-19 Otsuka Pharmaceut Factory Inc デキストラン含有肺塞栓形成予防用哺乳動物細胞懸濁液
EP2970882B1 (en) 2013-03-15 2018-11-28 AlloSource Cell repopulated collagen matrix for soft tissue repair and regeneration
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10251990B2 (en) 2016-04-29 2019-04-09 Fenwal, Inc. System and method for processing, incubating, and/or selecting biological cells
EP3238760B1 (en) * 2016-04-29 2019-10-02 Fenwal, Inc. System and method for selecting and culturing cells
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10274495B2 (en) 2016-12-21 2019-04-30 Fenwal, Inc. System and method for separating cells incorporating magnetic separation
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656841A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US20210395693A1 (en) * 2018-10-26 2021-12-23 Guy MARTI Method and apparatus for mesenchymal stem cells isolation and purification
EP3968992A4 (en) * 2019-05-15 2023-06-21 Stemcyte, Inc. PACKAGING AND SHIPPING HIGH CONCENTRATION CELLS
WO2021144995A1 (ja) * 2020-01-16 2021-07-22 ＰｕＲＥＣ株式会社 高純度間葉系幹細胞
JP2024511064A (ja) 2021-03-23 2024-03-12 テルモ ビーシーティー、インコーポレーテッド 細胞捕獲及び増殖
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034135A (en) 1982-12-13 1991-07-23 William F. McLaughlin Blood fractionation system and method
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
AU604054B2 (en) * 1986-08-11 1990-12-06 Baxter International Inc. Blood cell washing systems and methods
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5234608A (en) * 1990-12-11 1993-08-10 Baxter International Inc. Systems and methods for processing cellular rich suspensions
AU686823B2 (en) * 1994-06-06 1998-02-12 Case Western Reserve University Biomatrix for tissue regeneration
US5707996A (en) * 1995-11-06 1998-01-13 Macleod Pharmaceuticals, Inc. Pharmaceutical solution and methods for preparation thereof
JP2000508911A (ja) * 1996-04-19 2000-07-18 オシリス セラピューティクス，インコーポレイテッド 間葉幹細胞を用いる骨の再生および増強
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
EP1007631B2 (en) * 1997-07-14 2009-02-18 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
ES2258329T3 (es) 1998-03-18 2006-08-16 Osiris Therapeutics, Inc. Celulas madre mesenquimaticas para la prevencion y tratamiento de respuestas inmunes en trasplantes.
CA2328425A1 (en) * 1998-05-22 1999-12-02 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
FR2787463B1 (fr) 1998-12-21 2001-03-30 Neurotech Preparation de cellules de mammifere eventuellement transfectees avec un gene codant pour une substance active et les compositions les contenant
JP2002325572A (ja) * 2000-12-25 2002-11-12 Univ Osaka 外来物質の導入方法
US20030054331A1 (en) * 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US7514075B2 (en) * 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US20050095228A1 (en) * 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US8105580B2 (en) * 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
CA2849201A1 (en) * 2001-12-07 2003-07-03 Macropore Biosurgery, Inc. Adipose-derived cell processing unit
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US9597395B2 (en) * 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US7585670B2 (en) * 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US8404229B2 (en) * 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
ITTO20020311A1 (it) * 2002-04-10 2003-10-10 Medestea Int Spa Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t
ZA200404101B (en) 2003-05-26 2005-03-07 Reliance Life Sciences Pvt Ltd In vitro culture of Mesenchymal Stem Cells (MSC) and a process for the preparation thereof for therapeutic use.
AU2004260937B2 (en) 2003-06-25 2010-05-13 Macropore Biosurgery Inc. Systems and methods for separating and concentrating regenerative cells from tissue
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
JP3828905B2 (ja) * 2004-08-05 2006-10-04 株式会社Ｒ＆Ｄセルサイエンス・オプショナルメディコ 局所麻酔薬を含有する細胞凝集抑制剤
WO2006135854A2 (en) * 2005-06-10 2006-12-21 Board Of Regents, The University Of Texas System Antiseptic compositions
AU2006292203A1 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US7888119B2 (en) * 2005-10-14 2011-02-15 University Of Central Florida Research Foundation, Inc. Tissue substitutes comprising stem cells and reduced ceria
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
WO2007089798A2 (en) 2006-01-30 2007-08-09 University Of Virginia Patent Foundation Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof
CN101448527B (zh) 2006-05-19 2013-12-18 香港大学 细胞-基质微球，制备方法和应用
AU2007285057B2 (en) 2006-08-15 2013-08-01 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
CA2668330C (en) 2006-11-03 2016-02-02 Aastrom Biosciences, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
JP2008139106A (ja) * 2006-11-30 2008-06-19 Sysmex Corp 骨髄穿刺液収容具及び骨髄穿刺液濾過方法
US20080152630A1 (en) 2006-12-07 2008-06-26 Irene Ginis Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue
CN101210232B (zh) * 2006-12-28 2012-07-18 天津昂赛细胞基因工程有限公司 一种间充质干细胞保存液
US20110262402A1 (en) 2007-09-07 2011-10-27 Masahiko Kuroda Therapeutic and prophylactic agents for arthritis
JP5394932B2 (ja) 2007-11-02 2014-01-22 日本ケミカルリサーチ株式会社 ヒト間葉系幹細胞含有医薬組成物
MX362512B (es) 2008-08-14 2019-01-22 Mesoblast Int Sarl Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
US8217128B2 (en) 2008-09-04 2012-07-10 Amyris, Inc. Farnesene interpolymers
US10476476B2 (en) 2016-12-15 2019-11-12 Murata Manufacturing Co., Ltd. MEMS resonator with suppressed spurious modes

Also Published As

Publication number Publication date
AR073069A1 (es) 2010-10-13
AU2009281809A1 (en) 2010-02-18
US20230089901A1 (en) 2023-03-23
US20100068191A1 (en) 2010-03-18
JP7580202B2 (ja) 2024-11-11
JP2018109052A (ja) 2018-07-12
AR123811A2 (es) 2023-01-18
CA2733985A1 (en) 2010-02-18
AU2009281809B2 (en) 2015-09-17
US20140105872A1 (en) 2014-04-17
JP2017081972A (ja) 2017-05-18
JP2015071610A (ja) 2015-04-16
JP6025329B2 (ja) 2016-11-16
DK2318519T3 (en) 2017-01-16
JP2023052211A (ja) 2023-04-11
WO2010019886A1 (en) 2010-02-18
US8637004B2 (en) 2014-01-28
MX2011001730A (es) 2011-03-24
EP2318519A4 (en) 2013-07-24
CA2733985C (en) 2016-07-12
US20180008642A1 (en) 2018-01-11
JP2020120671A (ja) 2020-08-13
EP4477742A3 (en) 2025-02-26
NZ602248A (en) 2014-03-28
IL211214A0 (en) 2011-04-28
NZ591146A (en) 2012-10-26
BRPI0917993A2 (pt) 2017-10-10
JP2012500214A (ja) 2012-01-05
EP2318519B1 (en) 2016-10-05
EP2318519A1 (en) 2011-05-11
ES2608974T3 (es) 2017-04-17
EP3124601A1 (en) 2017-02-01
EP4477742A2 (en) 2024-12-18
ZA201101858B (en) 2011-11-30
US20200197444A1 (en) 2020-06-25
MX362512B (es) 2019-01-22
BRPI0917993B1 (pt) 2020-12-29

Similar Documents

Publication Publication Date Title
BRPI0917993B8 (pt) composições de célula-tronco mesenquimal purificada
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
WO2013078170A8 (en) Purification of anti-c-met antibodies
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
BR112012027915A2 (pt) nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EA201490420A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
BRPI0924617A8 (pt) Compostos heterociclicos de fenoximetila
EA201291050A1 (ru) Комбинация лекарств с протеинсвязывающими пролекарствами
EP2601951A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEMORRH HORSES CAUSED BY BLOOD GRANULAR MATERIALS
MX2013001842A (es) Composiciones de plasma rico en plaquetas.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MESOBLAST INTERNATIONAL SARL (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF